Antazoline

This classification denotes a histamine-1 receptor antagonist with the molecular formula C17H19N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DHA8014SS1, chemically known as 4,5-dihydro-n-phenyl-n-phenylmethyl-1h-imidazole-2-methanamine but generally known as antazoline, which bears US NIH Compound Identifier 2200. Antazoline most often comes in base, 7-theophyllineacetate, hydrochloride, mesylate, methanesulfonate, nitrate, and phosphate forms. European Medicines Agency schedules Antazoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05526MIG. The term ANTAZOLINE is an International Non-Proprietary Name. World Health Organization schedules antazoline in its Anatomical Therapeutic Chemical (ATC) Classification. ANTAZOLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule antazoline under HS 29332990 and SITC 51573. As of Q4 2014, ANTAZOLINE remains the US FDA Preferred Term for this commodity. Antazoline bears US NLM identifiers UMLS ID C0003143 and NCI Concept Code C61638. SMILES: N(CC1=NCCN1)(CC1CCCCC1)C1CCCCC1.